Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06359041 · ClinicalTrials.gov registry record · Phase 1

RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis

A Phase 1 study of Generalized Myasthenia Gravis (gMG), sponsored by Cabaletta Bio.

Active
Registry status
Phase 1
Development phase
12
Enrollment target
17
Study locations

NCT06359041 is a Phase 1 study of Generalized Myasthenia Gravis (gMG) that is active but no longer recruiting, run by Cabaletta Bio. The registered enrollment target is 12 participants, below the 58-participant average among 4 other Generalized Myasthenia Gravis (gMG) trials with a reported enrollment target (79% lower). The trial reports 17 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06359041, a Phase 1 study of Generalized Myasthenia Gravis (gMG), is active but no longer recruiting, sponsored by Cabaletta Bio.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
12 participants
Enrollment target
17
Study locations

Study Summary

RESET-MG: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Participants with Generalized Myasthenia Gravis

Conditions Studied

Generalized Myasthenia Gravis (gMG)

Interventions

  • BIOLOGICAL CABA-201

Study Locations (17)

California

  • University of California Irvine - Orange
  • UC Davis, Department of Neurology - Sacramento
  • University of California, San Francisco - San Francisco

Texas

  • Baylor College of Medicine Neurology Department - Houston
  • Houston Methodist Hospital - Houston
  • University of Texas MD Anderson Cancer Center - Houston

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston
  • University of Massachusetts Chan Medical School - Worcester

New York

  • Columbia University - New York
  • University of Rochester Medical Center - Rochester

Colorado

  • University of Colorado - Aurora

Florida

  • Mayo Clinic Florida - Jacksonville

Illinois

  • Northwestern Memorial Hospital - Chicago

Kansas

  • University of Kansas Medical Center - Kansas City

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2024-12-17
Est. Completion 2029-09
Phase Phase 1

Sponsor

Cabaletta Bio

6 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06359041

The ClinicalTrials.gov registry entry for NCT06359041 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 58-participant average among 4 other Generalized Myasthenia Gravis (gMG) trials with a reported enrollment target (79% lower). The listed sponsor is Cabaletta Bio, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Generalized Myasthenia Gravis (gMG) appearing as the primary indexed condition, and to 1 intervention - of which CABA-201 is the first listed.

NCT06359041 reports 17 study locations spanning 11 distinct geographic areas - top geographies include California, Texas, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06359041 about?

NCT06359041 is a clinical study titled "RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis". RESET-MG: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Participants with Generalized Myasthenia Gravis

What is the current status of trial NCT06359041?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2024-12-17. Estimated completion is 2029-09.

What conditions does trial NCT06359041 study?

This clinical trial studies the following conditions: Generalized Myasthenia Gravis (gMG).

What interventions are being tested in trial NCT06359041?

The interventions under investigation include: CABA-201 (BIOLOGICAL).

Who is sponsoring clinical trial NCT06359041?

This trial is sponsored by Cabaletta Bio, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06359041 being conducted?

This trial has 17 study locations across California, Colorado, Florida, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Generalized Myasthenia Gravis (gMG)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Generalized Myasthenia Gravis (gMG)

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.